{"title": "Lower costs associated with late-preterm steroid therapy", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/pharmaceuticals.xml", "value": "Lower costs associated with late-preterm steroid therapy"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2019/03/190312092524.htm"}], "link": "https://www.sciencedaily.com/releases/2019/03/190312092524.htm", "summary": "An analysis of a previous study has found more evidence to support giving the steroid betamethasone to pregnant women at risk of late-preterm delivery (between 34 and 36 weeks of gestation), according to new research. Hospital stays for infants whose mothers received the drug cost less on average, compared to stays for infants whose mothers did not take the drug.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/pharmaceuticals.xml", "value": "An analysis of a previous study has found more evidence to support giving the steroid betamethasone to pregnant women at risk of late-preterm delivery (between 34 and 36 weeks of gestation), according to new research. Hospital stays for infants whose mothers received the drug cost less on average, compared to stays for infants whose mothers did not take the drug."}, "published": "Tue, 12 Mar 2019 09:25:24 EDT", "published_parsed": [2019, 3, 12, 13, 25, 24, 1, 71, 0], "id": "https://www.sciencedaily.com/releases/2019/03/190312092524.htm", "guidislink": false}